This website uses cookies
Read our Privacy policy and Terms of use for more information.
Sep 8, 2026
Ultragenyx shares plunge 44% after its Angelman drug misses both Phase 3 endpoints. Plus, FDA trial scrutiny and major biotech deals.
Sep 3, 2026
Novartis pauses eight autoimmune CAR-T trials after three deaths, while Roche, Medtronic and Big Pharma keep dealmaking at full speed.
Sep 1, 2026
Lilly bets up to $2.875B on Merida, BioNTech ends a colorectal cancer vaccine trial, and Mounjaro adds a cardiovascular-risk indication.
Aug 27, 2026
FDA approves Revolution Medicines’ Rasonque after it extends median survival from 6.7 to 13.2 months in metastatic pancreatic cancer, plus biotech deal news.
Aug 25, 2026
Merck and Moderna’s mRNA cancer vaccine wins Phase 3 as FDA approves Genglycos and puts Regenxbio’s RGX-121 back on hold.
Aug 11, 2026
AI-designed viruses work in the lab, Replimune wins accelerated approval, Takeda targets narcolepsy at its source, and biotech IPOs rebound.
Aug 6, 2026
California rejects a pharma duty to innovate as KKR buys Integer, Pfizer expands cuts, and Lilly outpaces Novo in the GLP-1 race.
Aug 4, 2026
AstraZeneca and BMS reportedly explore a $400B combination as Curium buys Lantheus and Novo’s ziltivekimab misses Phase 3.
Jul 30, 2026
Altimmune’s obesity drug reduces heavy-drinking days, Freenome wins FDA approval, and mosquitoes expand the infectious-disease map.
